Кардиоваскулярная терапия и профилактика

Расширенный поиск

Анемия – независимый фактор риска неблагоприятных сердечно-сосудистых исходов у женщин

Полный текст:


Анемия является состоянием, наиболее часто встречающимся у женщин. Наличие анемии служит независимым предиктором неблагоприятного исхода при различных сердечно-сосудистых заболеваниях (ССЗ). Разобраны основные способы коррекции анемии у пациенток с ССЗ, приведены достоинства и недостатки различных терапевтических стратегий.


Об авторах

С. Н. Терещенко
Московский государственный медико-стоматологический университет Росздрава. Москва

И. В. Жиров
Московский государственный медико-стоматологический университет Росздрава. Москва

Т. М. Ускач
Московский государственный медико-стоматологический университет Росздрава. Москва

Список литературы

1. National Center for Health Statistics. Available at:<>. Accessed on December 14, 2005.

2. Sarnak M., Tighiouart H., Manjunath G. et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk In Communities (ARIC) study. JACC 2002; 40: 27-33.

3. Wu W, Rathore S, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 123076.

4. Al-Ahmed A., Rand W., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. JACC 2002; 39: 1780-6.

5. Ezekowitz J., McAlister F., Armstrong R. Anemia is common in eart failure and is associated with poor outcomes: insight from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003; 107: 223-5.

6. Hampl H., Sternberg C., Berweck S., et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol 2002; 58(Suppl 1): S73-96.

7. Reis S., Holubkov R., Smith C.A., et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001; 141: 735-41.

8. Al Falluji N., Lawrence-Nelson J., Kostis J., et al. Myocardial Infarction Data Acquisition System (MIDAS#8) Study Group. Effect of anemia on 1-year mortality in patients with acute myocardial infarction. Am Heart J 2002; 144: 636-41.

9. Arant C., Wessel T., Olson M., et al. Hemoglobin Level Is an Independent Predictor for Adverse Cardiovascular Outcomes in Women Undergoing Evaluation for Chest Pain. Results From the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. JACC 2004; 43: 2009-14.

10. Foley R., Parfrey P., Harnett J., et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61.

11. Metivier F., Marchais S., Guerin A., et al. Pathophysiology of anemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000; 15(Suppl3): 14-8.

12. Horwich T., Fonarow G., Hamilton M., et al. Anemia Is Associated Wth Worse Symptoms, Greater Impairment in Functional Capacity and a Significant Increase in Mortality in Patients With Advanced Heart Failure. JACC 2002; 39: 1780-6.

13. McClellan W., Flanders W., Langston R., et al. Anemia and Renal Insufficiency Are Independent Risk Factors for Death among Patients with Congestive Heart Failure Admitted to Community Hospitals: A Population-Based Study. J Am Soc Nephrol 2002; 13: 1928-36.

14. Ezekowitz J., McAlister F., Armstrong P. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107: 223-5.

15. Androne A., Katz S., Lund L., et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107: 226-9.

16. Ezekowitz J., Franijic N., Chang W., et al. What is the relationship between anemia and survival in patients with CHF? A population-based analysis of 29302 patients. Circulation 2002; 106(Suppl II): 11-472.

17. Cromie N., Lee C., Struthers A. Anaemia in chronic Heart failure: what is its frequency in the UK and its underlying causes? Heart 2002; 87: 377-8.

18. Felker G., Stough W., Shaw L., et al. Anaemia and coronary artery disease severity in patients with heart failure. Eur J Heart Failure 2006; 8: 54-7.

19. Hubert P., Wells G., Blajchman M., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340: 409-17.

20. Ely E., Bernard G. Transfusions in critically ill patients. N Engl J Med 1999; 340: 467-8.

21. Welch H., Meehan K., Goodnough L. Prudent strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 393-402.

22. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996; 84: 732-47.

23. Rao S., Jollis J., Harrington R., et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-62.

24. Schwengel R., Gottlieb S., Fisher M. Protein-energy malnutrition in patients with ischemic and nonischemic dilated cardiomyopathy and congestive heart failure. Am J Cardiol 1994; 73: 908-10.

25. King D., Smith M., Chapman T., et al. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing 1996; 25: 144-9.

26. Weil J., Colin J., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.

27. Silagy C., McNeil J., Donnan G., et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84-9.

28. Donnelly S., Posen G., Ali M. Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 1991; 14:271-6.

29. Goch J., Birgegard G., Danielson B., et al. Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 1996; 73: 403-6.

30. Kooistra M., Niemantsverdriet E., van Es A., et al. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 1998; 13(1): 882-8.

31. Macdougall I., Tucker B., Thompson J., et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-9.

32. Fishbane S., Frei G., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-6.

33. Silverberg D., Blum M., Peer G., et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-7.

34. Silverberg D., Blum M., Agbaria Z., et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int 1999; 55(Suppl 69): 79-85.

35. Silverberg D., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. JACC 2001; 37: 1775-80.

36. Mancini D., Katz S., Lang C. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-9.

37. Linde T., Wkstrom B., Andersson L. Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease. Scand J Urol Nephrol 1996; 30:115-20.

38. Low-Friedrich I., Grutzmacher P., Marz W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11:54-60.

39. Goldberg N., Lundin A., Delano B. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992; 124: 424-7.

40. Foley R., Parfrey P., Morgan J., et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric LV hypertrophy or LV dilatation. J Am Soc Nephrol 1998; 9: 208-10.

41. Wald M., Gutnisky A., Borda E. Erythropoietin modified the cardiac action of ouabain in chronically anaemic uraemic rats. Nephron 1995; 71: 190-6.

42. Wald M., Borda E., Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 1996; 167: 461-8.

43. Wu H., Lee S., Liu X. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Dvelopment 1999; 126: 3597-605.

44. Kuriyama S., Hopp L., Yoshida H., et al. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 1996; 9: 426-31.

45. Sowade O., Gross J., Sowade B., et al. Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta. J Lab Clin Med 1997; 129:97-105.

46. Silverberg D.S., Wexler D., Blum M. The Use of Subcutaneous Erythropoietin and Intravenous Iron for the Treatment of the Anemia of Severe, Resistant Congestive Heart Failure Improves Cardiac and Renal Function and Functional Cardiac Class, and Markedly Reduces Hospitalizations. JACC 2000; 35: 1737-44.

Для цитирования:

Терещенко С.Н., Жиров И.В., Ускач Т.М. Анемия – независимый фактор риска неблагоприятных сердечно-сосудистых исходов у женщин. Кардиоваскулярная терапия и профилактика. 2006;5(8):117-120.

For citation:

Tereshchenko S.N., Zhirov I.V., Uskach T.M. Anemia – an independent risk factor of adverse cardiovascular outcomes in women. Cardiovascular Therapy and Prevention. 2006;5(8):117-120. (In Russ.)

Просмотров: 14

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)